Shots:
1cBio & Lee's Pharmaceutical have entered into a licensing agreement granting Lee's Pharm exclusive rights to develop & commercialize OC-3, a preclinical PARP1 inhibitor, in China & certain countries in SE Asia
As per the deal, 1cBio will receive an upfront payment, development milestones & potential sales milestone payments totaling ~$27M, as well as…
